Cited by 400Radiopharmaceutical Chemistry and ApplicationsLymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

The DOI matches its Crossref record.

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

Kaminski, M S, Zasadny, K R, Francis, I R, Fenner, M C, Ross, C W, Milik, A W, Estes, J, Tuck, M, Regan, D, Fisher, S, Glenn, S D, Wahl, R L·1996·Journal of Clinical Oncology

DOI 10.1200/jco.1996.14.7.1974

Open this paper in CoChat — free account

Abstract

PURPOSE: The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for radioimmunotherapy, treatment using radiolabeled antibodies. We conducted a phase I dose-escalation trial to assess the toxicity, tumor targeting, and efficacy of nonmyeloablative doses of an anti-CD20 monoclonal antibody (anti-B1) labeled with iodine-131 (131I) in 34 patients with B-cell lymphoma who had failed chemotherapy. PATIENTS AND METHODS: Patients were first given tracelabeled doses of 131I-labeled anti-B1 (15 to 20 mg, 5 mCi) to assess radiolabeled antibody biodistribution, and then a radioimmunotherapeutic dose (15 to 20 mg) labeled with a quantity of 131I that would deliver a specified centigray dose of whole-body radiation predicted by the tracer dose. Whole-body radiation doses were escalated from 25 to 85 cGy in sequential groups of patients in 10-cGy increments. To evaluate if radiolabeled antibody biodistribution could be optimized, initial patients were given one or two additional tracer doses on successive weeks, each dose preceded by an infusion of 135 mg of unlabeled anti-B1 one week and 685 mg the next. The unlabeled antibody dose resulting in the most optimal tracer biodistribution was also given before the radioimmunotherapeutic dose. Later patients were given a single tracer dose and radioimmunotherapeutic dose preceded by infusion of 685 mg of unlabeled anti-B1. RESULTS: Treatment was well tolerated. Hematologic toxicity was dose-limiting, and 75 cGy was established as the maximally tolerated whole-body radiation dose. Twenty-eight patients received radioimmunotherapeutic doses of 34 to 161 mCi, resulting in complete remission in 14 patients and a partial response in eight. All 13 patients with low-grade lymphoma responded, and 10 achieved a complete remission. Six of eight patients with transformed lymphoma responded. Thirteen of 19 patients whose disease was resistant to their last course of chemotherapy and all patients with chemotherapy-sensitive disease responded. The median duration of complete remission exceeds 16.5 months. Six patients remain in complete remission 16 to 31 months after treatment. CONCLUSION: Nonmyeloablative radioimmunotherapy with 131I-anti-B1 is associated with a high rate of durable remissions in patients with B-cell lymphoma refractory to chemotherapy.

Integrity signals

Registry

Crossref · 10.1200/jco.1996.14.7.1974

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 101–200 of 400

FDG-PET Determination of Metabolically Active Tumor Volume and Comparison with CT.
Zasadny, K., Kison, P. V., Francis, I., & Wahl, R. (1998) · Clinical Positron Imaging · doi:10.1016/s1095-0397(98)00007-7 · Cited by 58
Self-citation
Radioimmunotherapy for B-cell non-Hodgkin lymphoma
Witzig, T. E. (2006) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2006.05.002 · Cited by 54
Review of clinical radioimmunotherapy
Pohlman, B. L., Sweetenham, J. W., & Macklis, R. M. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.3.445 · Cited by 52
Human antiglobulin response to foreign antibodies: therapeutic benefit?
DeNardo, G. L., Bradt, B. M., Mirick, G. R., et al. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0350-y · Cited by 51
“Anti-CD20 RIT using tositumomab and ibritumomab also deplete normal B-cells for several months because large amounts of unlabeled anti-CD20 mAb are given before the radiolabeled mAb [35, 40].”
Background
History of antibody therapy for non-Hodgkin’s lymphoma
Forero, A., & LoBuglio, A. F. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.10.002 · Cited by 52
Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
Koral, K. F., Dewaraja, Y. K., Li, J., et al. (2000) · PubMed · Cited by 51
Self-citation
Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
Dillman, R. O. (2006) · Clinical and Experimental Medicine · doi:10.1007/s10238-006-0087-6 · Cited by 50
“Table 2 Phase I clinical trials with anti-CD20 radiolabelled monoclonal antibodies for relapsed and transformed indolent B-cell lymphoma [30, 31]”
Background
Radioimmunotherapy for non-Hodgkin's lymphomas: A historical perspective
Press, O. W. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70053-0 · Cited by 50
Monoclonal antibody therapy for lymphoma
Campbell, P., & Marcus, R. E. (2003) · Blood Reviews · doi:10.1016/s0268-960x(03)00005-5 · Cited by 49
The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab
Wahl, R. L. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70055-4 · Cited by 49
Self-citation
Construction and Characterization of a Fusion Protein of Single-Chain Anti-CD20 Antibody and Human β-Glucuronidase for Antibody-Directed Enzyme Prodrug Therapy
Haisma, H. J., Sernee, M. F., Hooijberg, E., et al. (1998) · Blood · doi:10.1182/blood.v92.1.184.413k26_184_190 · Cited by 49
A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma
Rohatiner, A. Z. S., Radford, J. A., Deakin, D. P., Earl, H. M., Love, S., Price, O., Wilson, A., & Lister, T. A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1822 · Cited by 49
Accuracy of 131I tumor quantification in radioimmunotherapy using SPECT imaging with an ultra-high-energy collimator: Monte Carlo study.
Dewaraja, Y. K., Ljungberg, M. H., & Koral, K. F. (2000) · PubMed · Cited by 47
Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies
Richman, C. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00136-0 · Cited by 47
Lorvotuzumab mertansine: antibody-drug-conjugate for CD56⁺ multiple myeloma
Berdeja, J. G. (2014) · Frontiers in bioscience · doi:10.2741/4202 · Cited by 46
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
Tuscano, J. M., OʼDonnell, R. T., Miers, L. A., Kroger, L. A., Kukis, D. L., Lamborn, K. R., Tedder, T. F., & DeNardo, G. L. (2003) · Blood · doi:10.1182/blood-2002-08-2629 · Cited by 46
“The therapeutic potential of RIT in patients with NHL has been shown by a number of investigators utilizing numerous B-cell-specific targets including CD20, CD19, CD22, and HLA-DR10 (Lym-1) (8-15).”
Background
Current status of cancer therapy with radiolabeled monoclonal antibody
Oriuchi, N., Higuchi, T., Hanaoka, H., Iida, Y., & Endo, K. (2005) · Annals of Nuclear Medicine · doi:10.1007/bf03027399 · Cited by 47
Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate 211At-rituximab against non-Hodgkin's lymphoma cells
Aurlien, E., Larsen, R. H., Kvalheim, G., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1453 · Cited by 46
“When conjugated to the β- mitting isotopes 131I (Press et al, 1995; Kaminski et al, 1996) or 90Y (Knox et al, 1996), responses in up to 86% were seen (Multani and Grossbard, 1 Liu et al, 1998).”
Method
Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
Lindén, O., Tennvall, J., Cavallin-Ståhl, E. K., et al. (1999) · PubMed · Cited by 46
What are cancer patients willing to pay for prophylactic epoetin alfa?
Ortega, A., Dranitsaris, G., & Puodziunas, A. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12 · Cited by 63
A model for potential tumor immunotherapy based on knowledge of immune mechanisms responsible for spontaneous abortion
CHECK, J. H., Nazari, P., Goldberg, J., Yuen, W., & Angotti, D. (2001) · Medical Hypotheses · doi:10.1054/mehy.2001.1333 · Cited by 45
Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy.
Steffens, M. G., Boerman, O. C., Oyen, W. J. G., et al. (1999) · PubMed · Cited by 45
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644.1644_1644_1652 · Cited by 45
Monoclonal Antibody Therapy for Lymphoma
Dillman, R. O. (2001) · Cancer Practice · doi:10.1046/j.1523-5394.2001.009002071.x · Cited by 45
Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens
Treon, S. P., Shima, Y., Grossbard, M. L., et al. (2000) · Annals of Oncology · doi:10.1093/annonc/11.suppl_1.s107 · Cited by 44
Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
Loke, K. S. H., Padhy, A. K., Ng, D. C., Goh, A. S. W., & Divgi, C. R. (2011) · World Journal of Nuclear Medicine · doi:10.4103/1450-1147.89780 · Cited by 44
“[30] By these calculations, the administered dose to deliver a 75 cGy total-body dose of 131I to 634 NHL patients undergoing 131I tositumomab therapy varied from 43 to 275 mCi.[31] In tositumomab and 131I tositumomab dose escalation studies, the radiation dose was administered to patients, defined by dosimetry, correl…”
Background
Clinical promise of tumour immunology
Scott, A. M., & Cebon, J. S. (1997) · The Lancet · doi:10.1016/s0140-6736(97)90016-7 · Cited by 45
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
Rajendran, J. G., Fisher, D. R., Gopal, A. K., et al. (2004) · PubMed · Cited by 42
Monoclonal antibodies and therapy of human cancers
Funaro, A., Horenstein, A. L., Santoro, P., Cinti, C., Gregorini, A., & Malavasi, F. (2000) · Biotechnology Advances · doi:10.1016/s0734-9750(00)00043-4 · Cited by 41
Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy
Waldmann, T. A., & Morris, J. C. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90003-0 · Cited by 42
Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues
Silverman, D. H. S., Delpassand, E. S., Torabi, F., Goy, A. H., McLaughlin, P. J., & Murray, J. L. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.006 · Cited by 42
Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody
Maeda, T., Yamada, Y., Tawara, M., et al. (2001) · International Journal of Hematology · doi:10.1007/bf02982552 · Cited by 42
“Similarly, cases where the patient developed HAMA, but not clinical symptoms associated with it, were recorded [20,21].”
Background
Pretargeted α Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N‴-Tetraacetic Acid-Biotin
Yao, Z., Zhang, M., Garmestani, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0171 · Cited by 41
Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14.
Francisco, J. A., Donaldson, K. L., Chace, D. F., Siegall, C. B., & Wahl, A. F. (2000) · PubMed · Cited by 41
Are Radiometal-Labeled Antibodies Better Than Iodine-131–Labeled Antibodies: Comparative Pharmacokinetics and Dosimetry of Copper-67–, Iodine-131–, and Yttrium-90–Labeled Lym-1 Antibody in Patients with Non-Hodgkin's Lymphoma
DeNardo, G. L., DeNardo, S. J., OʼDonnell, R. T., et al. (2000) · Clinical Lymphoma · doi:10.3816/clm.2000.n.010 · Cited by 41
Apoptosis-Related Gene and Protein Expression in Human Lymphoma Xenografts (Raji) After Low Dose Rate Radiation Using 67 Cu-2IT-BAT-Lym-1 Radioimmunotherapy
Kroger, L. A., DeNardo, G. L., Gumerlock, P. H., et al. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/10849780152389401 · Cited by 41
Use of Integrated SPECT/CT Imaging for Tumor Dosimetry in I-131 Radioimmunotherapy: A Pilot Patient Study
Dewaraja, Y. K., Wilderman, S. J., Koral, K. F., et al. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0568 · Cited by 39
“16 In step 1 (tracer administration), on day 0, patients received an infusion of unlabeled (cold) tositumomab, followed by an infusion of tositumomab labeled with 185 MBq (5 mCi) of I-131.”
Self-citation
Radioimmunodetection and therapy of breast cancer
DeNardo, S. J. (2005) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2004.12.001 · Cited by 39
Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas
Zinzani, P. L., Magagnoli, M., Bendandi, M., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008388824069 · Cited by 39
Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis
Wang, Y.-Z., Ff, T., Yan, M., Zhang, J.-M., Liu, Q., Lu, J.-Y., Zhou, W.-B., Yang, H., & Li, J. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12265 · Cited by 38
Radiochemistry: A Hot Field with Opportunities for Cool Chemistry
Bowden, G. D., Scott, P. J. H., & Boros, E. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c01050 · Cited by 37
Instituto de Pesquisas Energéticas e Nucleares
Associada, A. (2006) · Cited by 37
Cure of incurable lymphoma
DeNardo, G. L., Sysko, V., & DeNardo, S. J. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.06.038 · Cited by 37
A Novel Platform for Radioimmunotherapy: Extracorporeal Depletion of Biotinylated and 90 Y-Labeled Rituximab in Patients with Refractory B-Cell Lymphoma
Lindén, O., Kurkus, J., Garkavij, M., et al. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.457 · Cited by 36
Adenovirus-mediated wild-type-p53-gene expression sensitizes TNF-resistant tumor cells to TNF-induced cytotoxicity by altering the cellular redox state
Shatrov, V. A., Ameyar‐Zazoua, M., Bouquet, C., Cai, Z., Stancou, R., Haddada, H., & Chouaı̈b, S. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000101)85:1 · Cited by 25
Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing
DeNardo, G. L., Juweid, M. E., White, C. A., et al. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00109-3 · Cited by 36
“[37] have done so for non-myeloablative RIT for NHL.”
Background
Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlínková, G., Booth, B. J. M., Batra, S. K., et al. (1999) · PubMed · Cited by 36
Update: A Revolution in the Treatment of Non-Hodgkin's Lymphoma
DeNardo, G. L., OʼDonnell, R. T., Oldham, R. K., et al. (1998) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1998.13.213 · Cited by 36
Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam.
Ruan, S., O’Donoghue, J. A., Larson, S. M., et al. (2000) · PubMed · Cited by 33
Immunocytoma: A Retrospective Analysis From St Bartholomew's Hospital—1972 to 1996
Papamichael, D., Norton, A. J., Foran, J. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2847 · Cited by 33
90Yttrium-Labeled Complementarity-Determining-Region-Grafted Monoclonal Antibodies for Radioimmunotherapy: Radiolabeling and Animal Biodistribution Studies
Govindan, S. V., Shih, L. B., Goldenberg, D. M., et al. (1998) · Bioconjugate Chemistry · doi:10.1021/bc980040g · Cited by 32
Nuclear imaging methods for non-invasive drug monitoring
Bhatnagar, A., Hustinx, R., & Alavi, A. A. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00055-1 · Cited by 32
Radioimmunotherapy in follicular lymphoma
Illidge, T., & Morschhauser, F. (2011) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2011.03.005 · Cited by 31
Physical and chemical properties of radionuclide therapy
Wessels, B. W., & Meares, C. F. (2000) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(00)80048-x · Cited by 31
Comparative Dosimetric Evaluation of Nanotargeted 188 Re-(DXR)-Liposome for Internal Radiotherapy
Chang, C.-H., Stabin, M. G., Chang, Y., Chen, L., Chen, M., Chang, T., Lee, T., & Ting, G. (2008) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0489 · Cited by 31
“26,27 In clinical trials, patients received escalating whole-body radiation doses, starting at 25 cGy and increasing in 10-cGy increments until MTD (75 cGy) was determined to be useful for safe treatment planning.”
CD22-directed monoclonal antibody therapy for lymphoma
Siegel, A. B., Goldenberg, D. M., Cesano, A., et al. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00240-9 · Cited by 31
Technological Advances in Radioimmunotherapy
Dearling, J. L. J., & Pedley, R. B. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.03.016 · Cited by 31
Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia
Wiseman, G. A., Leigh, B. R., Erwin, W. D., et al. (2003) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497803765036337 · Cited by 30
Anti-HLA-DR/anti-DOTA Diabody Construction in a Modular Gene Design Platform: Bispecific Antibodies for Pretargeted Radioimmunotherapy
DeNardo, D. G., Xiong, C., Shi, X.-B., et al. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/10849780152752128 · Cited by 30
Radioimmunotherapy for Non-Hodgkin Lymphoma : Historical Perspective and Current Status
Emmanouilides, C. E. (2007) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.47.43 · Cited by 30
The Emerging Role Of Radioimmunotherapy In Haematological Malignancies
Illidge, T., & Johnson, P. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01926.x · Cited by 30
“Impressive responses have also been seen with `tracer' doses of radiolabelled anti-CD20 antibodies, even before the `therapeutic' doses of RIT have been administered (Kaminski et al, 1996).”
BackgroundMethodInfluential
Milestones in the Development of Lym-1 Therapy
DeNardo, G. L., OʼDonnell, R. T., Rose, L., et al. (1999) · Hybridoma · doi:10.1089/hyb.1999.18.1 · Cited by 29
Systemic targeted radionuclide therapy: Potential new areas
Wong, J. Y. C. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.05.029 · Cited by 29
Image‐guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies
Dogra, P., Butner, J. D., Nizzero, S., Ruiz-Ramírez, J., Noureddine, A., Peláez, M. J., Elganainy, D., Yang, Z., Le, A., Goel, S., et al. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1628 · Cited by 28
Development and evaluation of a model-based downscatter compensation method for quantitative I-131 SPECT
Song, N., Du, Y., He, B., et al. (2011) · Medical Physics · doi:10.1118/1.3590382 · Cited by 28
Tumor Retention of 186 Re-MAG3, 111 In-DTPA and 125 I Labeled Monoclonal Antibody G250 in Nude Mice with Renal Cell Carcinoma Xenografts
Steffens, M. G., Kranenborg, M. H. G. C., Boerman, O. C., et al. (1998) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1998.13.133 · Cited by 28
Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma
Coiffier, B. (2002) · Blood Reviews · doi:10.1016/s0268-960x(02)00059-0 · Cited by 28
Combining Yttrium 90–Labeled Ibritumomab Tiuxetan with High-Dose Chemotherapy and Stem Cell Support in Patients with Relapsed Non-Hodgkin's Lymphoma
Winter, J. N. (2004) · Clinical Lymphoma · doi:10.3816/clm.2004.s.005 · Cited by 27
A Monte Carlo study of energy deposition at the sub-cellular level for application to targeted radionuclide therapy with low-energy electron emitters
Emfietzoglou, D., Bousis, C., Hindorf, C., et al. (2006) · Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms · doi:10.1016/j.nimb.2006.12.055 · Cited by 27
Feasibility and Safety of Outpatient Bexxar® Therapy (Tositumomab and Iodine I 131 Tositumomab) for Non-Hodgkin's Lymphoma Based on Radiation Doses to Family Members
Rutar, F. J., Augustine, S. C., Kaminski, M. S., Wahl, R. L., Siegel, J. A., & Colcher, D. M. (2001) · Clinical Lymphoma · doi:10.3816/clm.2001.n.022 · Cited by 26
Self-citation
Radioimmunotherapy for non-Hodgkin’s lymphoma: A review for radiation oncologists
Macklis, R. M., & Pohlman, B. L. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.05.030 · Cited by 27
Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
Kaminski, M. S., Estes, J., Zasadny, K. R., et al. (2000) · Blood · doi:10.1182/blood.v96.4.1259.h8001259_1259_1266 · Cited by 27
Self-citation
The Importance of Antibody-Specificity in Determining Successful Radioimmunotherapy of B-Cell Lymphoma
Illidge, T., Cragg, M. S., McBride, H. M., et al. (1999) · Blood · doi:10.1182/blood.v94.1.233.413a25_233_243 · Cited by 27
Radioimmunotherapy for NHL: Experience of90Y-Ibritumomab Tiuxetan in Clinical Practice
Hagenbeek, A. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190310001616944 · Cited by 26
Monoclonal antibody therapy of B cell lymphoma
Weiner, G. J., & Link, B. K. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.3.375 · Cited by 26
Improving the efficacy of radioimmunotherapy for non‐Hodgkin lymphomas
Palanca-Wessels, M. C., & Press, O. W. (2010) · Cancer · doi:10.1002/cncr.24801 · Cited by 25
Radioimmunotherapy as a Therapeutic Option for Non-Hodgkin’s Lymphoma
Macklis, R. M. (2007) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2007.02.003 · Cited by 25
Autologous hematopoietic cell transplantation: An update for clinicians
Hamadani, M. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.952662 · Cited by 23
How and why does radioimmunotherapy work?
Macklis, R. M. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.04.008 · Cited by 24
Radioimmunotherapy for non-Hodgkin’s lymphoma
Emmanouilides, C. E. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00237-9 · Cited by 24
Transformation in Follicular Lymphoma: Biology, Prognosis, and Therapeutic Options
Wong, E., & Dickinson, M. J. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0258-4 · Cited by 23
“Studies published in the 1990s described the efficacy of radioimmunoconjugates in B-cell lymphomas [29, 30].”
Background
Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin’s lymphoma: initial experience
Bienert, M., Reisinger, I., Srock, S., Humplik, B. I., Reim, C., Krössin, T., Avril, N. E., Pezzutto, A., & Munz, D. L. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1770-7 · Cited by 23
Design of a Modular Immunotoxin Connected by Polyionic Adapter Peptides
Kleinschmidt, M., Rudolph, R., & Lilie, H. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00141-4 · Cited by 22
Comparative Physical and Pharmacologic Characteristics of Iodine-131 and Yttrium-90: Implications for Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma
Leonard, J. P., Siegel, J. A., & Goldsmith, S. J. (2003) · Cancer Investigation · doi:10.1081/cnv-120016421 · Cited by 22
“Several clinical trials have investigated the efficacy of RIT in patients with low- to intermediate-grade NHL.”
BackgroundInfluential
Radiation physics and genetic targeting: new directions for radiotherapy*
Wheldon, T. E. (2000) · Physics in Medicine and Biology · doi:10.1088/0031-9155/45/7/201 · Cited by 22
The management of adult aggressive non-Hodgkin’s lymphomas
Couderc, B., Dujols, J.-P., Mokhtari, F., Norkowski, J.-L., Slawinski, J.-C., & Schlaifer, D. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00037-2 · Cited by 21
“Monoclonal antibodies such as the anti-CD20 IDEC-C2B8 humanized antibody [232,233] or the iodine-123 radiolabeled anti-CD20 antibody [234,235] are currently being investigated.”
Background
Radioimmunotherapy for B‐Cell Non‐Hodgkin Lymphoma
Witzig, T. E. (2010) · doi:10.1002/9780470613214.ch6 · Cited by 22
Improving the treatment of non‐Hodgkin lymphoma with antibody‐targeted radionuclides
Sharkey, R. M., Karacay, H., & Goldenberg, D. M. (2010) · Cancer · doi:10.1002/cncr.24802 · Cited by 21
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies
Audicio, P. F., Castellano, G., Tassano, M. R., et al. (2011) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2011.01.026 · Cited by 21
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate177Lu-Lilotomab Satetraxetan
Blakkisrud, J., Holtedahl, J. E., Løndalen, A. M., Dahle, J., Bach‐Gansmo, T., Holte, H., Rudå, S. N., Kolstad, A., & Stokke, C. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.195347 · Cited by 21
“131I-tositumomab is administered to limit the WB dose to 75 cGy (27).”
Background
Radiometals as Payloads for Radioimmunotherapy for Lymphoma Lymphoma
DeNardo, G. L., Kennel, S. J., Siegel, J. A., & DeNardo, S. J. (2004) · Clinical Lymphoma · doi:10.3816/clm.2004.s.002 · Cited by 21
Biopharmaceuticals as Targeting Vehicles forIn situRadiotherapy of Malignancies
Reilly, R. M. (2005) · doi:10.1002/9783527620982.ch20 · Cited by 21
Myeloablative Anti-CD20 Radioimmunotherapy +/- High-Dose Chemotherapy Followed by Autologous Stem Cell Support for Relapsed/Refractory B-Cell Lymphoma Results in Excellent Long-Term Survival
Wagner, J. Y., Schwarz, K. B., Schreiber, S. C., Schmidt, B., Wester, H., Schwaiger, M., Peschel, C., von Schilling, C., Scheidhauer, K., & Keller, U. B. (2013) · Oncotarget · doi:10.18632/oncotarget.1037 · Cited by 20
“Thereupon several studies using radionuclide-labeled anti-CD20 antibodies in non-myeloablative doses showed high response rates in patients with recurrent or refractory indolent lymphomas [5-10].”
Background
Single-Cell Dosimetry for Radioimmunotherapy of B-Cell Lymphoma Patients with Special Reference to Leukemic Spread
Hindorf, C., Emfietzoglou, D., Lindén, O., et al. (2007) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2007.347 · Cited by 20
“A clinical observation compatible with this notion is the report by Kaminski et al. 5 that relapse often solely occurs in sites that are not previously known to have a lymphoma involvement.”
Radionuclide therapy dose calculations: what accuracy can be achieved?
Flower, M. A., & McCREADY, V. R. (1997) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050174 · Cited by 20
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update
Cicone, F., Santo, G., Bodet‐Milin, C., Cascini, G. L., Kraeber‐Bodéré, F., Stokke, C., & Kolstad, A. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.12.006 · Cited by 20
Listeriolysin O as cytotoxic component of an immunotoxin
Bergelt, S., Frost, S., & Lilie, H. (2009) · Protein Science · doi:10.1002/pro.130 · Cited by 19
Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3ζ recombinant gene
Yu, K., Hu, Y., Tan, Y., et al. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802064958 · Cited by 19
Radioimmunoimaging and radioimmunotherapy: Will these be routine procedures?
Delaloye, A. B. (2000) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2000.7440 · Cited by 19
High Dose Therapy and Autologous Stem Cell Transplantation in Follicular non-Hodgkin's Lymphoma
Freedman, A. S., Gribben, J. G., & Nadler, L. M. (1998) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199809092678 · Cited by 19

Authors: Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., & Wahl, R. L.
Affiliations: University of Michigan (US)
ORCID: Kaminski, M S
Francis, I R
Tuck, M
Glenn, S D
Wahl, R L
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1996-07
Volume: 14
Issue: 7
Pages: 1974-1981
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1996.14.7.1974
OpenAlex: W1892026381
Cited by: 396
References: 0
Citations by year: 2024: 2 · 2023: 6 · 2022: 5 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 6
FWCI: 28.19
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ca056794-08, 5p01ca042768-03)
National Cancer Institute (R01-CA-56794, P0-1 CA42768)
National Center for Research Resources (M-01RR00042, M01RR000042)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords: iodine-131, anti-CD20 monoclonal antibody, radioimmunotherapy, B-cell lymphoma, treatment toxicity, hematologic toxicity, tumor targeting, tissue distribution, complete remission, relapsed/refractory lymphoma, indolent lymphoma, transformed lymphoma, chemotherapy-refractory disease
MeSH terms: Adult, Aged, Antibodies, Monoclonal, Dose-Response Relationship, Radiation, Female, Humans, Iodine Radioisotopes, Male, Middle Aged, Remission Induction, Lymphoma, B-Cell, Radioimmunotherapy, Antigens, CD20

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks